There are many differences in exclusion/inclusion criteria between these trials.
Moreover, patients who have failed prior therapies are much less likely to respond to a given treatment than treatment naive or all-comers. Also, Oncosec/UCSF was selecting patients who had very few exhausted CD8-positive Tcells - even if we question the biomarker assay, the fact remains that the enrolled patients did not have "hot" tumors. These were the worst of the worst immunologically; there was no such requirement in the other trials.
News 
Market Data 
Discover 
